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In order to verify the protein enriched from pooled human sera to be a
lung-speciﬁc protein surfactant protein-D (SP-D), we performed
peptide mass ﬁngerprinting (PMF)-based protein identiﬁcation.
MASCOT search results of the obtained PMF unequivocally demon-
strated that it is identical to human SP-D. Meanwhile, we performed
MALDI-QIT-TOF mass spectrometry-based N-glycomic analysis of the
recombinant human SP-D produced in murine myeloma cells. The
obtained mass spectra of N-glycans from the recombinant SP-D
demonstrated that the recombinant protein is almost exclusively
modiﬁed with core-fucosylated N-glycans [1].
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
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Wako-shi, Saitama 351-0198, Japanata accessibility With this articleDValue of the data
 The enriched protein was veriﬁed to be surfactant protein-D (SP-D) by peptide mass ﬁngerprinting.
 Any contaminated proteins other than SP-D were not identiﬁed by our proteomic analysis.
 A commercially available SP-D was found to be almost completely core-fucosylated by N-glycomic
analysis.1. Data, experimental design, materials and methods
This data article describes veriﬁcation of the enriched SP-D from commercially available human
pooled sera and results of N-glycomic analysis of a commercially available recombinant human SP-D
produced in murine myeloma cells.2. SP-D veriﬁcation
The veriﬁcation of SP-D was performed by resolving the enriched SP-D by SDS-PAGE, in-gel
digestion of the corresponding band, peptide mass ﬁngerprinting, and MASCOT search. Brieﬂy, human
serum SP-D was enriched as described in our main research article [1]. The enriched SP-D fraction
was resolved by SDS-PAGE under reducing conditions and visualized by CBB staining. The 43-kDa
band was excised from the gel, cut into 1 mm3 pieces, and destained and dehydrated with 50% ACN/
100 mM NH4HCO3. Proteins in the gel pieces were then reduced with 10 mM DTT in 100 mM
NH4HCO3 at 56 °C for 1 h and alkylated with 55 mM IAA in 100 mM NH4HCO3 at room temperature in
the dark for 45 min. The gel pieces were rinsed in 100 mM NH4HCO3 and dehydrated with 50% ACN/
100 mM NH4HCO3, and then 100% ACN and then dried completely using a vacuum centrifuge con-
centrator. The dried gel pieces were rehydrated again with 10 ng/μl trypsin in 50 mM NH4HCO3
solution on ice, and then incubated at 37 °C for 16 h. The sample was heated at 90 °C for 5 min to
inactivate trypsin and the resulting peptides were extracted with ACN/water/TFA (66:33:0.1, v/v/v).
The extracts were then dried and desalted using a ZipTipμ-C18 tip (Millipore, Billerica, MA). The eluate
(0.5 μl) and DHB matrix solution (0.5 μl) were deposited on a μFocus MALDI target plate (Hudson
Surface Technology, Inc., Fort Lee, NJ) and left to dry at room temperature. All mass spectrometry was
performed on a MALDI-QIT-TOF mass spectrometer (AXIMA-Resonance, Shimadzu/Kratos, U.K.). Ions
were formed by a pulsed nitrogen UV laser (λ¼337 nm) in both the positive and negative ion modes.
A pulsed gas, He, was used for ion cooling in the ion trap and Ar was used for CID fragmentation. The
DHB matrix solution was prepared by dissolving 2.5 mg of DHB in 1 ml of ACN/0.1% TFA in water (2:3,
v/v). Protein identiﬁcation was performed with MASCOT search (Matrix Science, London, U.K.) using
the Swiss-Prot database 2014_12 by peptide mass ﬁngerprinting with the following MASCOT
E. Ito et al. / Data in Brief 5 (2015) 707–711 709parameters; miss cleavage: 2, peptide mass tolerance: 0.1 Da, taxonomy: human, ﬁxed modiﬁcations:
carbamidomethyl (C), variable modiﬁcations: oxidation (M), Pyro-Glu (N-term Q) (Figs. 1, 2).3. N-Glycomic analysis of a recombinant SP-D
N-glycomic analysis of the recombinant SP-D was performed by liberating N-glycans with PNGase
F from the protein portion, ﬂuorescence labeling of the liberated N-glycans, and analyzing the
resulting ﬂuorescent N-glycans with a MALDI-QIT-TOF-mass spectrometer. Brieﬂy, N-glycans in a
commercially available recombinant human SP-D (R&D Systems) which was produced in murine
myeloma N0 cells by manufacturer, were released by digestion with PNGase F and the liberated N-
glycans were labeled with BlotGlyco (Sumitomo Bakelite, Tokyo, Japan) according to the manu-
facturer’s instructions. The resulting ﬂuorescence-labeled glycans were then analyzed by MALDI-QIT-
TOF mass spectrometry as described formerly (Fig. 3).100
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Fig. 1. Protein identiﬁcation of the SP-D-derived peptides. The SP-D enriched from pooled human sera was veriﬁed by pro-
teomic analysis based on PMF. The obtained PMF data (A) were queried for protein identiﬁcation using a Swiss-Prot database.
The results unequivocally demonstrated that the queried protein is identical to human SP-D (B).
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Fig. 3. N-glycosylation proﬁling of recombinant human SP-D. N-Glycans in a commercially available recombinant human SP-D
(R&D Systems) produced in murine myeloma N0 cells were released by digestion with PNGase F and the liberated N-glycans
were labeled with BlotGlyco (Sumitomo Bakelite, Tokyo, Japan) according to the manufacturer’s instructions. The resulting
ﬂuorescence-labeled N-glycans were analyzed by MALDI-QIT-TOF mass spectrometry. The results unequivocally demonstrated
the presence of a core-fucose in the recombinant SP-D N-glycans as revealed by conﬁrming the characteristic fragment ion at
m/z 797 (data not shown).
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Fig. 2. Protein identiﬁcation of the SP-D-derived peptides. In the course of N-glycomic analysis of the enriched human serum
SP-D [1], the protein portion of SP-D remained in a PAGE gel after liberation of N-glycans was veriﬁed by proteomic analysis
based on PMF. The obtained PMF data (A) were queried for protein identiﬁcation using a Swiss-Prot database. The results
unequivocally demonstrated that the protein remained in a PAGE gel is human SP-D (B).
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Supplementary data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2015.09.017.Reference
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